Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD4956 · 1 trial · 1 indication
To assess the safety and tolerability of AZD4956 monotherapy and in combination with anti-cancer agent(s).
PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the participants withdraw from study treatment or receive another anti-cancer therapy prior to progression.
To assess the safety and tolerability of AZD4956 monotherapy and in combination with anti-cancer agent(s).
| Arm | Type | Description |
|---|---|---|
| Module 1 Part A: AZD4956 monotherapy (Dose escalation) | EXPERIMENTAL | Participants will receive AZD4956 as monotherapy at ascending dose levels. |
| Module 2 Part A: AZD4956 + saruparib (Dose escalation) | EXPERIMENTAL | Participants will receive AZD4956 at ascending dose levels in combination with saruparib. |
| Module 2 Part A Optional PD backfill cohort: AZD4956 + saruparib | EXPERIMENTAL | Participants will receive AZD4956 in combination with saruparib. |
| Module 2 Part A Optional PD backfill cohort: Saruparib monotherapy | EXPERIMENTAL | Participants will receive saruparib monotherapy. |
| Module 2 Part A Optional non-PD backfill cohort: AZD4956 + saruparib | EXPERIMENTAL | Participants with metastatic castrate resistant prostate cancer (mCRPC) will receive AZD4956 in combination with saruparib. |
| Module 2 Part B: AZD4956 + saruparib (Dose expansion) | EXPERIMENTAL | Participants will receive AZD4956 in combination with saruparib. |
| Name | Type | Description |
|---|---|---|
| AZD4956 | DRUG | AZD4956 will be administered orally. |
| Saruparib | DRUG | Saruparib will be administered orally. |
Core Inclusion Criteria: * Documented locally advanced or metastatic solid tumour malignancy. * Eastern cooperative oncology group (ECOG) performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to screening and first day of dosing. * Minimum life expectancy ≥ 12 weeks. * ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
AZD4956 is an investigational small molecule being developed for the treatment of solid tumours, specifically advanced or metastatic homologous recombination deficient solid tumours. It is currently being studied as a monotherapy and in combination with other anti-cancer agents in a Phase 1 clinical trial.
AZD4956 is being studied in patients with homologous recombination deficient solid tumours, indicating it targets tumours with defects in the homologous recombination repair pathway. The specific molecular target of AZD4956 has not been disclosed in the available information.
AZD4956 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting a Phase 1 clinical trial to evaluate the drug in patients with advanced or metastatic solid tumours.
AZD4956 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to evaluate the safety and efficacy of AZD4956 as a monotherapy and in combination with other anti-cancer agents.
AZD4956 is being evaluated in a Phase 1 clinical trial with the identifier NCT07446855. This study is recruiting participants with advanced or metastatic homologous recombination deficient solid tumours and is being conducted in the United States, Australia, Japan, South Korea, Spain, and the United Kingdom.